HUB Organoid Technology represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug development services using its living organoid biobanks. Frost & Sullivan Best Practices Awards recognize companies in various regional and… Continue reading Juvenescence lands $76m led by Abu Dhabi healthcare giant M42
Orgullosamente Colombianos.